Knocking out growth hormone receptors specifically in fat tissue extended healthspan in mice through a precise molecular cascade involving AMPK-SIRT1-acetylated PPARγ signaling. This intervention improved cognitive performance, muscle strength, and bone mass while reducing age-related inflammation and metabolic dysfunction—without the adverse developmental effects seen with global growth hormone suppression. The targeted approach fundamentally reprogrammed adipose tissue into a high-plasticity, low-inflammation depot that enhanced systemic metabolic resilience. This represents a sophisticated evolution in longevity science, moving beyond crude hormone suppression toward precision tissue engineering. The AMPK pathway's central role suggests existing compounds like metformin might partially mimic these benefits. However, translating genetic knockouts to human therapeutics remains challenging, likely requiring novel drugs or gene therapies. The finding that fat tissue can serve as a metabolic control center for whole-body aging opens new therapeutic avenues, though the mouse model's relevance to human adipose biology and aging patterns requires validation through clinical studies.